Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

First Author: Leila Reyes 

Journal/preprint name: medRxiv 

Tags: Neutrophils, proteomics, LDN, ARDS, Type I IFN, platelets 

Summary 

This study reports on the proteomics and metabolomics analysis of peripheral blood neutrophils from patients with COVID-19 ARDS (CA; n=3), non-COVID-19 ARDS (NA; n=3-7), moderate COVID-19 (MC; n=3), and healthy controls (HC; n=4-7). For some analyses normal density neutrophils (NDN) and low density neutrophils (LDN; isolated from the PBMC layer) were analysed separately. LDN consisted of both mature (CD16+CD10+) and immature (CD16-CD10-) neutrophils. Due to the small samples sizes most conclusions will need further validation, but the data suggest that neutrophils in COVID-19 ARDS may have increased IFN I signalling, degranulation, and platelet binding compared to healthy controls. 

Research Highlights  

  1. Comparing the neutrophil proteome of COVID-19 ARDS patients to healthy controls highlights an increase in the type I interferon signalling pathway and in markers of platelet degranulation. 

  1. Mature LDN from moderate or ARDS COVID-19 patients show increased CD41 staining, suggesting increased binding to platelets, compared to NDN from healthy controls. Immature LDN from COVID-19 patients do not show increased CD41 staining. 

  1. NDN from ARDS COVID-19 patients have slightly decreased content of granule proteins compared to healthy controls. 

  1. NDN from ARDS COVID-19 patients have increased glucose content compared to healthy controls, the cause is unclear. 

  1. In vitro stimulation of healthy neutrophils with a TLR7/8 agonist under hypoxic conditions leads to an activated phenotype regarding surface receptors. 

Impact for COVID-19 research:  

No direct impact because the conclusions need further validation. 

Methodologies: 

  • Study Typecase study, in vitro 

  • Key Techniques: flow cytometry for activation markers, proteomics, metabolomics, extracellular flux analysis 

Limitations: 

  • Small group sizes; n=3 for COVID-19 ARDS and n=3 for moderate COVID-19. 

  • p-hacking obvious: the grouping & subsetting of the samples is not consistent throughout the manuscript, and comparisons are often illogical (e.g. why not compare NA directly to CA in Fig. 3?). 

  • Most statements in the text are based on comparisons that don’t show statistically significant differences. 

  • Patient characteristics are only provided for ARDS patients not for moderate patients or HC. Unclear whether non-COVID-19 ARDS patients also had viral infection.